An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects

Primary Biliary Cirrhosis Clinical Trial

Official title:

An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03082937
• Other study ID #: A4250-007
• Secondary ID: 2016-002923-27
• Status: Completed
• Phase: Phase 1
• Start date: January 31, 2017
• Est. completion date: March 8, 2017

Study information

• Verified date: March 2024
• Source: Ipsen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of the study are to assess the mass balance recovery after a single dose of carbon-14 [14C]-A4250 as a capsule and to provide plasma, urine and faecal samples for metabolite profiling and structural identification in healthy male subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: March 8, 2017
• Est. primary completion date: March 8, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy males

2. Age 30 to 65 years of age

3. Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator

4. Must be willing and able to communicate and participate in the whole study

5. Must have regular bowel movements (i.e., average stool production of =1 and =3 stools per day)

6. Must provide written informed consent

7. Must agree to use an adequate method of contraception

Exclusion Criteria:

1. Subjects who have received any IMP in a clinical research study within the previous 3 months prior to screening

2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee

3. Subjects who have previously been enrolled in this study

4. History of any drug or alcohol abuse in the past 2 years

5. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

6. Current smokers and those who have smoked within the last 12 months. A confirmed positive urine cotinine test at screening or admission

7. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months

8. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study

9. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening

10. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator

11. Confirmed positive drugs of abuse test result at screening or admission

12. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results

13. Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (CLcr) of <90 mL/min using the Cockcroft-Gault equation

14. History of cardiovascular, renal, hepatic, chronic respiratory or GI disease as judged by the investigator

15. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients

16. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active

17. Donation or loss of greater than 400 mL of blood within the previous 3 months

18. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.

19. Failure to satisfy the investigator of fitness to participate for any other reason

Related Conditions & MeSH terms

• Alagille Syndrome
• Cholestasis
• Cholestasis, Intrahepatic
• Liver Cirrhosis, Biliary
• Liver Diseases
• Orphan Cholestatic Liver Diseases
• Primary Biliary Cirrhosis
• Progressive Familial Intrahepatic Cholestasis

Intervention

Drug:
• 3 mg [14C]-A4250 capsule
Each subject will receive a single administration of 3 mg [14C]-A4250 capsule for oral administration containing not more than 4.3 MBq (116 µCi), in the fasted state.

Locations

Country	Name	City	State
United Kingdom	Quotient Clinical	Ruddington	Nottingham

Sponsors (1)

Lead Sponsor	Collaborator
Albireo

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess mass balance recovery of total radioactivity in urine	Amount excreted (Ae) and Ae as a percentage of the administered dose (% Ae), cumulative recovery (CumAe) and cumulative recovery expressed as a percentage of the dose (Cum%Ae)	Between pre-dose (admission to 0 hour) and post dose (ending on morning of discharge (up to day 10 depending on if mass balance cumulative recovery >90% or <1% of dose has been collected))
Primary	To assess mass balance recovery of total radioactivity in faeces	Amount excreted (Ae) and Ae as a percentage of the administered dose (% Ae), cumulative recovery (CumAe) and cumulative recovery expressed as a percentage of the dose (Cum%Ae)	Between pre-dose (admission to 0 hour) and post dose (ending on the morning of discharge (up to day 10 depending on if mass balance cumulative recovery >90% or <1% of dose has been collected))
Primary	Metabolite profiling of A4250 of plasma using liquid-chromatography-radio-detection with subsequent mass spectrometry as appropriate	Identification of the chemical structure of each metabolite accounting for greater than 10% of circulating radioactivity in plasma	Between pre-dose and up to 48 hours post dose
Primary	Metabolite profiling of A4250 of urine using liquid-chromatography-radio-detection with subsequent mass spectrometry as appropriate	Identification of the chemical structure of each metabolite accounting for greater than 10% of the dose in urine	Between pre-dose (admission to 0 hour) and post dose (ending on the morning of discharge (up to day 10 depending on if mass balance cumulative recovery >90% or <1% of dose has been collected))
Primary	Metabolite profiling of A4250 of faeces using liquid-chromatography-radio-detection with subsequent mass spectrometry as appropriate	Identification of the chemical structure of each metabolite accounting for greater than 10% of the dose in faeces	Between pre-dose (admission to 0 hour) and post dose (ending on the morning of discharge (up to day 10 depending on if mass balance cumulative recovery >90% or <1% of dose has been collected))